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Type 1 diabetes (T1D) is caused by interactions of genetic pre-
disposition, immunologic triggers, and environmental events 
leading to autoimmune-mediated pancreatic β-cell destruc-
tion and insulin deficiency, although some subjects show lack 
of autoantibodies to pancreatic islets. Regarding the time lag 
of complete β-cell mass loss in T1D, simple or unique patterns 
may not be identified, with some individuals progressing for 
more than several years. Contrary to T1D, type 2 diabetes 
(T2D), irrelevant of autoimmune-mediated β-cell destruction, 
is a heterogeneous disorder characterized by insidious onset 
and insulin resistance with relative insulin secretory dysfunc-
tion. Clinically, some diabetic patients exhibit autoimmune 
antibodies without insulin requirement. This biphasic type of 
diabetes is a special form of diabetes that is clinically similar to 
the early stage of T2D and pathophysiologically defined as a 
disorder of the autoimmune-mediated progressive β-cell dys-
function. To clarify different features from T1D and T2D, Zim-
met [1] introduced the eponym “latent autoimmune diabetes 
of adults” (LADA) to describe this subgroup of adult pheno-
typic T2D patients positive for autoantibodies. Based on the 
natural history of LADA, in which secretory β-cell dysfunc-
tion is prominently aggravated depending on the presence of 
antibodies seen in T1D, Stenstrom et al. [2] suggested LADA 
is not always a latent disease. Therefore, autoimmune diabetes 
in adults with slowly progressive β-cell failure might be a more 
adequate concept. The Immunology of Diabetes Society (IDS) 
has proposed criteria to standardize the definition of LADA: 
1) ≥35 years of age, 2) positive for at least 1 of the 4 antibodies 
commonly seen in T1D patients; islet cell autoantibodies 
(ICA), anti-glutamic acid decarboxylase (anti-GAD), Insulin-
oma-associated protein-2 antibodies (IA-2A), and insulin au-
toantibodies (IAA), and 3) not requiring insulin therapy with-
in the first 6 months after diagnosis [3].
 Regarding the genetic and immunologic characteristics in 
LADA, subjects with LADA show a type of difference from 
patients with T1D. First, compared with T1D, susceptibility 
genes are much less prevalent, but protective genes are more 
prevalent in LADA [4]. HLA alleles associated with T1D sus-
ceptibility are HLA DR3, DR4, and DQB1*0201 and 0302, 
while the alleles associated with T1D protection are DR2 and 
DQB1*0301 and 0602 [5,6]. These differences may partially 
explain the relatively late onset of LADA. Second, there are 
several differences in autoantibodies between T1D and LADA. 
Compared with T1D, anti-GAD and ICA are much more com-
mon than IAA, IA-2A, and zinc transporter 8 (ZnT8) antibod-
ies in subjects with LADA [7,8]. GAD is a neuronal enzyme 
involved in the synthesis of the neurotransmitter gamma-ami-
nobutyric acid. Anti-GAD is seen not only in a variety of auto-
immune neurologic disorders including stiff-man syndrome, 
autoimmune cerebellitis, brain stem encephalitis etc., but also 
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in autoimmune T1D. In clinical practice, anti-GAD is not only 
an important serological marker of predisposition to T1D but 
also the major pancreatic islet antibody for diagnosing T1D 
[9]. Of the anti-GAD subclasses, the IgG4 subclass is more fre-
quent in LADA than in T1D [10]. T1D and LADA also show 
different epitope specificity for anti-GAD. The middle or 
COOH-terminal portion of GAD was recognized by more than 
90% of sera from T1D compared with only 65% of LADA pa-
tients. In contrast, 20% of LADA patients’ sera bound to the 
NH2-terminal portion of GAD, compared with 5% of T1D 
patients [11].
 There are many controversial issues regarding prevalence of 
LADA. In previous epidemiological studies, LADA accounted 
for 2% to 12% of all cases of diabetes [1,8,12]. Some studies 
suggested that LADA accounts for approximately 10% of the 
patients initially diagnosed as T2D [13,14]. Despite several 
studies on the prevalence in the Korean population [15-17], 
controversy still remains on the accurate prevalence. Most 
studies tested for anti-GAD only when the patients were sus-
pected to have T1D. Recently, Hwangbo et al. [18] reported a 
4.3% prevalence of LADA in newly-diagnosed Korean T2D 
subjects regardless of their clinical characteristic at the time of 
presentation. Though Hwangbo et al. [18] indicated that 4.3% 
prevalence of anti-GAD positivity was similar to that in Japan, 
they did not thoroughly review the well-designed trials study-
ing the prevalence of LADA in Korea, where a recent-onset 
T2D Korean National Diabetes Program cohort showed a 4.4% 
prevalence by the positivity of circulating autoantibodies to 
pancreatic islet cell antigens (GAD, IA-2, and ZnT8) [19], as 
well as 5.1% to 5.3% prevalence in a single center trial [20,21]. 
Another limitation of the study conducted by Hwangbo et al. 
[18] is that the authors only evaluated for the anti-GAD, and 
not other autoantibodies such as ICA, IA-2A, and IAA. Based 
on the data, the prevalence of LADA in Korea may be around 
5% in T2D. However, the ambiguity in diagnosis criteria in 
previous studies such as age (more than 30 or 35 years), anti-
bodies (ICAs and anti-GAD, IA-2A, and IAA in IDS criteria, 
or anti-GAD, IA-2A, anti-ZnT8 in European NIRAD LADA 
group criteria), and period of insulin independence after diag-
nosis did not come to a conclusive answer regarding preva-
lence and incidence.
 Regarding the β-cell secretory dysfunction in LADA, sever-
al studies have reported the presence of a single autoantibody 
and/or lower anti-GAD titer is associated with older age, a slow-
er rate of disease progression, and lower risk of insulin depen-
dency. In contrast, the presence of multiple autoantibodies and/
or higher anti-GAD titer is associated with younger age, a fast-
er rate of disease progression, and higher risk of insulin de-
pendency [10,22]. Similar to the above-mentioned results, 
Hwangbo et al. [18] reported that high anti-GAD titer showed 
significantly lower C-peptide level and was more likely to re-
quire insulin treatment. A well-designed 12-year prospective 
study [23] showed diabetic subjects with multiple islet anti-
bodies (ICA, anti-GAD, IA-2A) are more prone to deteriorate 
in insulin secretory resulting in β-cell failure within 5 years, 
whereas patients with only anti-GAD or only ICA mostly de-
velop β-cell failure after 5 years. Though Hwangbo et al. [18] 
were unable to observe the natural course of the β-cells, a pro-
spective 36-month multicenter study in Korean diabetic sub-
jects showed 7.7% subjects with LADA were dependent on in-
sulin within 3 years, but true insulin dependency evidenced by 
multiple antibody positivity was not high and did not increase 
in Korean subjects [19]. Considering the characteristics of Ko-
rean patients with T2D, whose secretory β-cell dysfunction is 
a major contributing factor to the development and aggrava-
tion of hyperglycemia [24,25], a large scale nationwide pro-
spective study is warranted to verify the meaning of autoanti-
body positivity to pancreatic islets and the natural course of 
β-cell secretory dysfunction in LADA.
 Another controversy on subjects with LADA may be the 
relevance of metabolic syndrome. As described previously, 
T2D, irrelevant of autoimmune-mediated β-cell destruction, 
has a heterogeneous pathophysiology characterized by insulin 
resistance with relative insulin secretory dysfunction, but LADA 
is an autoimmune diabetes in adults with slowly progressive 
β-cell failure. Regarding islet autoantibodies in metabolic fea-
tures, LADA patients with multiple autoantibodies and/or a 
high titer of anti-GAD showed a higher risk of β-cell dysfunc-
tion and presence of other autoimmune disorders, but a lower 
prevalence of metabolic syndrome in Western populations [22]. 
Hwangbo et al. [18] could not find differences in the metabolic 
syndrome and its components including HOMA-IR between 
subjects with anti-GAD positive and subjects with anti-GAD 
negative, and suggested LADA in the Korean population might 
be different from LADA in the Caucasian population. Howev-
er, Lee et al. [20] showed that low C-peptide level and absence 
of metabolic syndrome were variables independently associat-
ed with the diagnosis of LADA.
 Due to the ambiguous pathophysiology and clinical charac-
teristics of LADA, no specific guideline for treatment of LADA 
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has been established. The primary defect in autoimmune dia-
betes is loss of insulin secretion. Insulin secretory capacity in 
LADA has been recognized as between T1D and T2D [23]. 
LADA patients have a faster decline in C-peptide levels com-
pared with patients with T2D [23,26], whereas a slower rate of 
decline compared with adult T1D [27]. Several Japanese stud-
ies demonstrated insulin treatment showed better preservation 
of β-cell function compared with sulfonylurea in ICA-positive 
and anti-GAD-positive phenotypic T2D subjects [28]. Anti-
inflammatory therapy that slows progression of β-cell destruc-
tion could be another option. Thiazoledinediones also might 
be of value in the treatment of LADA, because of the anti-in-
flammatory effect, as well as improving insulin sensitivity. 
LADA patients treated with rosiglitazone were reported to have 
greater β-cell preservation compared with a group of LADA 
subjects treated with insulin alone during a 3-year follow-up 
[29]. Recently, antigen-specific immunomodulation has been 
reported as potential treatment choice, such as GAD vaccine 
[30]. 
 LADA is not a rare disease, and many subjects are still un-
derdiagnosed. Without awareness, a correct diagnosis of LADA 
is not easy. Earlier correct diagnosis of LADA could help clini-
cians and patients to manage ongoing β-cell dysfunction. A 
large scale nationwide study to examine the natural course and 
clinical characteristics of subjects with LADA in Korean sub-
jects is essential to preserve β-cell function in subjects with 
LADA.
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